This site is intended for Healthcare professionals only.

Lupin launches generic Tobramycin Inhalation Solution USP in the US


Lupin launches generic Tobramycin Inhalation Solution USP in the US

Pharma Major Lupin has announced the launch of its Tobramycin Inhalation Solution USP, having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Tobramycin Inhalation Solution USP, 300 mg/5 ml is the generic equivalent of Novartis Pharmaceuticals Corporation’s Tobi 300 mg/5 ml. It is indicated for the management of cystic fibrosis patients with P aeruginosa.

Tobramycin Inhalation Solution USP, 300 mg/5 ml had annual sales of approximately USD 99 million in the US (IQVIA MAT April 2018).



Source: UNI
0 comment(s) on Lupin launches generic Tobramycin Inhalation Solution USP in the US

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted